Bioventus intends to sell $415 million worth of senior notes in a private offering.
The orthobiologics company said in an April 26 news release it plans to put the profits from the sale toward its acquisition of medical device company CartiHeal. The proceeds will go toward repaying outstanding debts, covering costs associated with the sale and other corporate purposes.
The senior notes are not registered under the Securities Act of 1933, meaning they cannot be offered or sold in the U.S.